NCT03335098

Study of VTD in Waldenstrom's Macroglobulinemia

A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.

Conditions

• Waldenstrom Macroglobulinemia
• Lymphoplasmacytic Lymphoma

Interventions

Type	Name	Description
DRUG	Bortezomib	Six 4-week cycles

Timeline

• Start date: 2016-11-21
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2017-11-07
• Last updated: 2017-11-07

Locations

2 sites across 1 country: South Korea